A perioperative uncontrollable bleeding in an elderly patient with acquired hemophilia A: a case report by Cortegiani, A et al.
CASE REPORT
A perioperative uncontrollable bleeding in an elderly
patient with acquired hemophilia A: a case report
Andrea Cortegiani, Vincenzo Russotto, Grazia Foresta, Francesca Montalto,
Maria Teresa Strano, Santi Maurizio Raineri & Antonino Giarratano
Department of Biopathology, Medical and Forensic Biotechnologies (DIBIMEF), Section of Anesthesiology, Analgesia, Emergency and Intensive
Care, Policlinico “P. Giaccone”, University of Palermo, Via del Vespro 129, 90100, Palermo, Italy
Correspondence
Andrea Cortegiani, Department of
Biopathology, Medical and Forensic
Biotechnologies (DIBIMEF), Section of
Anesthesiology, Analgesia, Emergency and
Intensive Care, Policlinico “P. Giaccone”,
University of Palermo, Via del Vespro 129,
90100, Palermo, Italy. Tel: 00390916552727;
Fax: 00390916552715;
E-mail: andreacortegiani@alice.it
Funding Information
No funding information provided.
Received: 12 April 2013; Revised: 27 May
2013; Accepted: 6 June 2013
doi: 10.1002/ccr3.2
Key Clinical Message
Acquired hemophilia A should be taken into account in the differential diagno-
sis of perioperative bleeding in patients without any apparent reason for acti-
vated partial thromboplastin time prolongation.
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Introduction
Acquired hemophilia A (AHA) is a rare and potentially
life-threatening hemorrhagic disorder. It is caused by the
production of autoantibodies against factor VIII (FVIII)
[1]. It could be associated with several underlying condi-
tions as pregnancy, autoimmune disorders, drugs, and
malignancies. However, etiology remains unknown in up
to 50% of cases [2]. Bleeding usually involves soft tissues,
muscles, insertion sites of vascular accesses, retroperito-
neal space and, eventually, traumatized tissues and organs.
The diagnosis of AHA is usually based on an isolated
prolongation of activated partial thromboplastin time
(APTT) in a bleeding patient without known coagulation
disorders, a low level of FVIII activity and a high level of
FVIII antibodies [3]. We report the case of a man admit-
ted to our general intensive care unit (ICU) because of a
perioperative uncontrollable acute bleeding, severe
anemia, and isolated prolongation of APTT.
Case Report
An 82-year-old Caucasian man presented to the emer-
gency room (ER) of the University General Hospital
(Policlinico P. Giaccone) in Palermo, Italy, because of a
3-day history of right lower back pain radiating to the
abdomen and superficial bruising on the right lumbar
region. The day before, he had fallen in the bathroom
during a lipothymic episode. Thus, his general physician
referred him to the ER, where he was admitted as “yellow
code” (necessitating urgent care). His past medical history
included hypertension (treated with carvedilol and furose-
mide), chronic renal failure (stage II) [4], glaucoma, and
cancer (hemicolectomy 7 years before and nephrectomy
6 months before). Once arrived to ER, he was febrile
(38°C), tachypnoic (26 breaths/min), and tachycardic
(106 beats/min). Noninvasive blood pressure was 110/
70 mmHg and peripheral O2 saturation was 99% on air.
Inspection revealed bruising on the legs and on the right
lumbar region. Physical examination revealed a rigid, ten-
der abdomen. Arterial blood gas analysis showed a pH of
7.49, PaCO2 of 23 mmHg, PaO2 of 104 mmHg, HCO
3
of 17.4 mEq/L, and a base excess of 4.9 mmol/L. Labo-
ratory tests revealed a hemoglobin (Hb) level of 7.6 g/dL,
white blood count of 18.56 9 103 lL, serum creatinine of
4.26 mg/dL, potassium of 7 mEq/L, and a myoglobin of
1025 ng/mL. His first-line coagulation parameters were
platelets 356 9 103 lL, international normalized ratio
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(INR) 0.96, APTT 101 sec (normal range 24–36 sec), and
fibrinogen 705 mg/dL. Once asked, the patient denied any
bleeding episodes or family history of coagulation disor-
ders. A computerized tomography (CT) with contrast
revealed an active retroperitoneal bleeding. As soon as
called on consultation, the surgeon suggested an explor-
ative laparotomy, due to the active retroperitoneal bleed-
ing and the recent trauma history. A preoperative dialysis
without heparin was executed because of the high potas-
sium level and the finding of peaked T-waves on electro-
cardiogram. After hemodialysis, potassium level decreased
to 3.9 mEq/L and the patient was conducted to the
operating theater where general anesthesia was induced
without complications. The explorative laparotomy
revealed a blood congested right ileo-psoas muscle with
an active, oozing and diffuse hemorrhage. Intraoperative
arterial blood gas analysis and coagulation tests showed a
reduction in Hb level (6.6 g/dL) and an APTT >220 sec.
The anesthesiologist started a transfusion of fresh frozen
plasma (FFP) and packed red blood cells (PRBCs). As an
adequate hemostasis was not achievable, the surgeon posi-
tioned two retroperitoneal drains and sutured the bleed-
ing abdominal wall. Then, the patient was admitted to
our ICU under mechanical ventilation and sedation.
Despite the preload optimization, he was hemodynamically
unstable and norepinephrine infusion was started. The in-
tensivist continued the transfusion of PRBCs and FFP and
required clotting factors dosages. FVIII level was <2%
(normal range: 50–150%). Lupus anticoagulant activity
test was negative. Suspecting an AHA, he requested the
dosage of FVIII inhibitors and the result was 20.64
Bethesda Units/mL. The hematologist suggested the
administration of FVIII inhibitor bypass activity (FEIBA,
Baxter AG, Vienna, Austria) 50 international units/kg
(I.U./kg) twice a day and methylprednisolone 125 mg
once a day. Despite antihemorrhagic therapy, clinical sta-
tus and coagulation tests did not improve significantly.
After an initial decrease (APTT 63 sec on day 1), APTT
remained >100 sec and Hb levels continued to lower.
Bleeding was clinically evident from the surgical wound,
requiring several changes of surgical dressing (Figs. 1 and
2). Moreover, it was also evident from arterial line and
venipuncture sites. On day 4, the intensivist, after a new
hematology consultation, started a second-line bypassing
therapy with recombinant activated FVII (rFVIIa; Novo-
Seven RT, Novo Nordisk AS, Bagsværd, Denmark)
90 lg/kg every 3 h and added a prothrombin complex
concentrate (UmanComplex D.I, Kedrion, Castelvecchio
Pascoli, Italy) 2000 I.U. twice a day. Immunosuppressive
therapy was shifted to dexamethasone 8 mg/die. On day
9, bleeding increased from the cited sites. Conjunctival
and mucosal hemorrhage and diffuse ecchymosis in the
back appeared. He died on day 11.
Discussion
AHA is a rare hemorrhagic disorder with an estimated
incidence of 0.2–1 million/year and a mortality rate of
7.9–22% [3]. Demographic and clinical data of 501
patients with AHA, included in the European Acquired
Haemophilia Registry (EACH2), have been recently pub-
lished [5]. According to previous case series, no associ-
ated medical condition is identified in 51.9% of cases [6].
The average age at diagnosis is 74 with a positive linear
correlation between incidence and age [5]. Cancer is asso-
ciated with AHA in 11.8% of cases. The relationship
Figure 1. New surgical dressing. Day 1: 8.30 AM.
Figure 2. Bleeding from surgical wound and insertion sites of
surgical drains. Day 1: 10.30 AM.
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between hematologic malignancies and production of
FVIII inhibitors is well established but the correlation
with solid tumors is still unclear [6]. Although cancer was
reported in the past medical history of our patient, a
review of his medical records revealed that both the colon
adenocarcinoma and the renal pelvis urothelioma were
treated with radical surgery and neither signs (i.e., physi-
cal examination and abdominal CT scan) nor symptoms
were suggestive of a cancer recurrence or metastases. The
cancer markers, CEA and CA19.9, dosed 1 month before
as part of a periodic follow-up, resulted within normal
range. Therefore, a definitive relationship between cancer
history and AHA could not be established. Associated
autoimmune disorders are present in 11.6% of AHA cases
[5]. In these patients, the level of inhibitors is usually
high and do not decrease with steroid therapy alone [6].
In our patient, despite the high level of inhibitors and the
poor response to steroidal therapy, the diagnosis of an
underlying autoimmune disease was refuted by negative
autoantibodies screening tests, negative personal and fam-
ily history and the absence of any other clinical finding
consistent with an autoimmune disorder. A drug-induced
AHA was excluded as his chronic therapy had remained
stable for years without previous bleeding episodes, even
during his previous two surgical interventions. Initial
bleeding event is spontaneous in the majority of cases
(77.4%). Trauma is recognized as the cause of the initial
bleeding episode in only 8.4% of cases [5]. Although rela-
tives reported a traumatic event during the lipothymic
episode, a source of bleeding was not identified during
surgery. Moreover, it could be possible that the lipothy-
mic episode was a consequence of the hypotension and
the low Hb level due to the underlying, spontaneous
bleeding. After a benefit-risk analysis, surgery represented
the first-line treatment because of the CT-scan finding of
an active retroperitoneal bleeding and history of trauma.
As soon as the diagnosis of AHA was confirmed, an anti-
hemorrhagic treatment strategy was promptly started.
Cornerstones of therapy are hemostatic treatment with
bypassing agents and inhibitor eradication with immuno-
suppressive therapy [7]. Bypassing agent is a definition
for a drug with the property of promoting thrombin gen-
eration bypassing platelets surface activity of activated
FVIII and IX (FVIIIa–FIXa, tenase complex) which is
lacking in AHA [8]. Both rFVIIa and FEIBA mechanisms
of action were reinterpreted in light of the cell-based
model of hemostasis which, in contrast to the coagulation
cascade model, provides an explanation of bleeding epi-
sodes in AHA in spite of two different, though converg-
ing, coagulation pathways [9]. The mechanism of action
of FEIBA mainly relies on the presence of the activated
factor X (FXa) complex with prothrombin (factor II, FII),
which protects FXa from inhibition and enhances the
formation of prothrombinase complexes on platelet sur-
faces. Conversely, rFVIIa acts activating small amounts of
FX on platelet surface bypassing tenase complex activity
and then promoting thrombin generation and fibrin clot
formation. FEIBA and rFVII are the only bypassing agents
coagulation factor concentrates available at the moment
for bleeding control in AHA [1, 2]. Although not directly
compared for AHA treatment, rFVIIa and FEIBA seem
equally efficacious for bleeding control, according to the
observational data of the EACH2 registry. We decided to
adopt FEIBA as the first-line bypassing agent [8]. Bypass-
ing therapy response was primarily monitored on a clini-
cal basis. As no adequate bleeding control was achieved
with FEIBA, NovoSeven was started as a second-line
bypassing therapy. UmanComplex D.I (containing FII,
FIX, and FX) was added as a prothrombin complex con-
centrate in order to supply a balanced coagulation factor
composition.
The aim of immunosuppressive therapy is to eradicate
the inhibitor suppressing its production by responsible
cell clone and to normalize the FVIII level [6]. Steroids
are the most commonly used drugs for this therapeutic
goal though several authors described their association
with cyclophosphamide. To date, no definitive data sup-
port combined steroids and cyclophosphamide therapy in
AHA [2, 10]. Although remission rate seems to be higher
with combined immunosuppressive therapy, final out-
come is not influenced by the initial immunosuppressive
regimen, possibly reflecting the higher morbidity (i.e.,
infections, cytopenia) associated with the combined
immunosuppressive therapy [10]. Moreover, advanced
age and comorbidities may preclude an aggressive
immunosuppressive treatment and influence the final
outcome.
Conclusion
Although AHA is a rare disease, it should be taken into
account in the differential diagnosis of elderly patients
with a history of recent onset bleeding and a prolonged
APTT. Identifying a relationship between AHA and an
associated disease could be challenging and even in our
patient’s case no definitive cause was found despite an
accurate review of old medical records and an extensive
investigation through imaging and laboratory tests. As
bypassing agents represent the first-line therapy, they
should be promptly started after laboratory diagnosis con-
firmation of AHA.
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